Alternative strategies for investing in corporate R&D (on the example of the global pharmaceutical industry)

Olga Yeremchenko

Economics of Science, 2018, vol. 4, issue 4

Abstract: During the last ten years, the largest pharmaceutical manufacturers significantly changed their approaches to the formation of their own strategies for capturing and retaining the leading positions in global markets. One of the key prerequisites was a decline in the return on investment in R&D: if in 2010 among the top 12 pharmaceutical companies of the world this indicator was 10,1%, then in 2017 it fell to 3,2%. At the same time, the cost of developing and launching new medicines has increased: from $1,2 billion to $2 billion in 2010–2017.The article analyzes the main reasons for the transformation of the strategies of the Big Pharma companies. It has been suggested that, in the context of a decline in payback in R&D, increased competition, a fall in public expenditure on the purchase of pharmaceuticals, and tightening of regulatory requirements, it is advisable for domestic companies to reorient the creation of corporate venture funds and investing in start-ups, and actively use the mergers and acquisitions strategy.

Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://ecna.elpub.ru/jour/article/viewFile/138/134 (application/pdf)

Related works:
Journal Article: Alternative strategies for investing in corporate R&D (on the example of the global pharmaceutical industry) (2018)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:abz:journl:y:2018:id:138

DOI: 10.22394/2410-132X-2018-4-4-309-317

Access Statistics for this article

More articles in Economics of Science from Delo Publishing house
Bibliographic data for series maintained by Кочетков Дмитрий Михайлович ().